

Product datasheet for RC203819L2V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

CD14 (NM_000591) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type: Lentiviral Particles

Product Name: CD14 (NM_000591) Human Tagged ORF Clone Lentiviral Particle

Symbol: **CD14**

Mammalian Cell

Selection:

None

Vector: pLenti-C-mGFP (PS100071)

mGFP Tag:

ACCN: NM_000591 **ORF Size:** 1125 bp

ORF Nucleotide

Sequence:

The ORF insert of this clone is exactly the same as(RC203819).

OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of

> reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

This clone was engineered to express the complete ORF with an expression tag. Expression **OTI Annotation:**

varies depending on the nature of the gene.

RefSeq: NM 000591.2

RefSeq Size: 1623 bp RefSeq ORF: 1128 bp Locus ID: 929

UniProt ID: P08571 **Cytogenetics:** 5q31.3 Domains: LRR

Protein Families: Adult stem cells, Druggable Genome, Embryonic stem cells, ES Cell Differentiation/IPS,

Transmembrane





CD14 (NM_000591) Human Tagged ORF Clone Lentiviral Particle - RC203819L2V

Protein Pathways: Hematopoietic cell lineage, MAPK signaling pathway, Pathogenic Escherichia coli infection,

Regulation of actin cytoskeleton, Toll-like receptor signaling pathway

MW: 40.08 kDa

Gene Summary: The protein encoded by this gene is a surface antigen that is preferentially expressed on

monocytes/macrophages. It cooperates with other proteins to mediate the innate immune response to bacterial lipopolysaccharide, and to viruses. This gene has been identified as a target candidate in the treatment of SARS-CoV-2-infected patients to potentially lessen or inhibit a severe inflammatory response. Alternative splicing results in multiple transcript

variants encoding the same protein. [provided by RefSeq, Aug 2020]